Influence of Chemotherapy on Postural Control in Women With Cancer

Aline Reinmann

Status: Completed

Conditions: Cancer, Gynecologic; Cancer, Breast

Study type: Observational

Funder types: Other

Identifiers

NCT04692168

105909

2020-01639 (Registry Identifier)

Details and patient eligibility

About

The aim of this study is to understand the strategies for adapting postural control in patients who have received chemotherapy treatment for gynaecological cancer.

Full description

Chemotherapy can cause many side effects, including peripheral neuropathies. Chemotherapy induced peripheral neuropathies (CIPN) are primarily sensory impairments that can alter the signals for somatosensory feedback and thus affect the postural control in the standing position. The objective of this study is to evaluate the impact of chemotherapy and peripheral neuropathies on postural control in the standing position. As balance maintenance is a complex construct involving different systems, this study will evaluate maintenance strategies during sensory disturbances in order to better understand post-chemotherapy coping strategies. These sensory disturbances concern vision (eyes closed) and the alteration of the somatosensory system (foam under the feet and vibration system). In addition, this study will evaluate balance in double task situations and dynamic stability. Given the consequent impact of chemotherapy and peripheral neuropathies on quality of life, a quality of life questionnaire will also be administered.

Enrollment: 35 patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Women

• between 18 and 65 years;
• with a gynaecological cancer about to start chemotherapy known to be neurotoxic (paclitaxel, docetaxel, nab-paclitaxel, or paclitaxel-carboplatin);
• able to stand upright for 30 s on a flat surface without assistance;
• able to provide written consent

Exclusion criteria

Women

• with pre-existing vestibular, uncorrectable visual, or somatosensory disorders or other pathologies altering postural control that would influence testing;
• with exposure to known neurotoxic chemotherapy (paclitaxel, docetaxel, nab-paclitaxel, vinorelbine, trastuzumab-emtansine, eribulin, or paclitaxel-carboplatin) that may have caused previous CIPN;
• with an inability to perform the test due to poor comprehension of instructions or psychological problems.

Trial design

35 participants in 1 patient group

Entire group

Description:

The group will be test prior and three months after a neurotoxic chemotherapy for gynecological cancer.